anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients receive bevacizumab and FOLFIRI chemotherapy (B-FOLFIRI) as in arm I. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes on day 1 and oral capecitabine once every 12 hours on days 1-14. Treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
The other arm was a 3-session brief intervention, with 2 sessions involving the adolescent and one session with the parent. Each of these individual sessions were 60 minutes.
PURPOSE OF REVIEW: There is significant need to improve diagnostic and therapeutic options for patients with cancer of unknown primary (CUP). In this review, we discuss the evolving landscape of molecular profiling in CUP.
RECENT FINDINGS: Molecular profiling is becoming accepted into the diagnostic work-up of CUP patients with tumour mutation profiling now described in international CUP guidelines. Although tissue-of-origin (ToO) molecular tests utilising gene-expression and DNA methylation have existed some time, their clinical benefit remains unclear. Novel technologies utilising whole genome sequencing and machine learning algorithms are showing promise in determining ToO, however further research is required prior to clinical application. A recent international clinical trial found patients treated with molecularly-guided therapy based on comprehensive-panel DNA sequencing had improved progression-free survival compared to chemotherapy alone, confirming utility of performing genomic profiling early in the patient journey. Small phase 2 trials have demonstrated that some CUP patients are responsive to immunotherapy, but the best way to select patients for treatment is not clear.
SUMMARY: Management of CUP requires a multifaceted approach incorporating clinical, histopathological, radiological and molecular sequencing results to assist with identifying the likely ToO and clinically actionable genomic alternations. Rapidly identifying a subset of CUP patients who are likely to benefit from site specific therapy, targeted therapy and/or immunotherapy will improve patient outcomes.
Recently the concerns about the Health-Related Quality of Life (HRQOL) have been increasing especially in chronic diseases. Rheumatic disease is a chronic disease, which can result in a functional disability and impaired HRQOL. Because of this chronic pain, patients with rheumatic disease have lower scores on HRQOL than general population. A several studies have indicated Ultracet as an add-on treatment to nonsteroidal antiinflammatory drugs(NSAIDs) for osteoarthritis(OA) pain, fibromyalgia pain and chronic low back pain significantly improved HRQOL, compared with placebo. We will use the KEQ-5D (a Korean version of the EQ-5D which is a health related quality of life questionnaire) to assess HRQOL. The KEQ-5D has been shown to be effectively sensitive in several rheumatic conditions. The study hypothesis is that the quality of life will be improved after Tramadol 37.5mg/Acetaminophen 325mg tablets administration in outpatients who need Tramadol 37.5mg/Acetaminophen 325mg tablets administration at the investigator's discretion. This is a multicenter, open-label, prospective, observational study to compare HRQOL using Korean version of EQ-5D before and after the treatment with Tramadol 37.5mg/Acetaminophen 325mg tablets and to assess the correlation among each measurement. Observational Study - No investigational drug administered
FIELD: medicine; pharmaceuticals.SUBSTANCE: invention refers to pharmaceutical industry, namely to a composition for treating diseases and symptoms selected from lower urinary tract symptoms (LUTS), erectile dysfunction (ED), benign prostatic hyperplasia (BPH), urinary incontinence, hyperactive urinary bladder (HUB). Dosage formulation for oral administration, selected from a solid dosage form or soft gel for treating diseases and symptoms selected from: lower urinary tract symptoms (LUTS), erectile dysfunction (ED), benign prostatic hyperplasia (BPH), urinary incontinence, hyperactive urinary bladder (HUB) containing 250 mg to 500 mg of therapeutic composition containing powder of dried cranberries and additionally cranberry seeds or cranberry flour, where additional cranberry seeds or cranberry flour are present in the therapeutic composition in amount of 15 % to 25 % of the weight of the dried cranberry fruit powder. Method of treating or relieving lower urinary tract symptoms (LUTS) in a subject in need thereof, wherein said method comprises administering to the subject one dosage form for oral administration. Method of treating urinary incontinence in a subject in need thereof, wherein said method comprises administering to the subject a single dosage form for oral administration. Method of treating a hyperactive urinary bladder (HUB) condition in a subject in need thereof, wherein said method comprises administering to the subject one dosage form for oral administration. Method of treating or alleviating the symptoms of benign prostatic hyperplasia (BPH) in a subject in need thereof, wherein said method comprises administering to the subject a single dosage form for oral administration. Method of treating erectile dysfunction (ED) in a subject in need thereof, wherein said method comprises administering to a subject one dosage form for oral administration. Method of treating diseases and symptoms selected from lower urinary tract symptoms (LUTS), urinary incontinence, hyperactive urinary bladder (HUB), benign prostatic hyperplasia (BPH), erectile dysfunction (ED), in a subject in need thereof, wherein said method comprises administering an oral dosage form to a subject.EFFECT: composition described above is effective for treating diseases and symptoms selected from lower urinary tract symptoms (LUTS), erectile dysfunction (ED), benign prostatic hyperplasia (BPH), urinary incontinence, hyperactive urinary bladder (HUB).31 cl, 2 dwg, 9 tbl, 3 ex
Considering that theory-based educational practices alone are not sufficient in the management of HT and that a multifaceted perspective must be developed, in addition to the education based on the ADL nursing model, the conscious awareness approach, which is effective in stress management with its easy integration into daily life, has also been included in this program. In this way, individuals can gain experience and reach self-awareness as a result of theory and skill-based training and feel more motivated to adopt healthy lifestyle behaviors. Multicomponent interventions offer a more comprehensive approach by combining a variety of methods, such as mindfulness, exercise, and dietary changes, as well as educational programs. Such integrated interventions can positively impact both individuals' knowledge and lifestyle habits, providing more effective results in the management of HT and contributing to long-term health improvements.

In this context, this study aimed to evaluate the effect of the training program, structured according to Roper, Logan and Tierney's ADL nursing model and supported by awareness, on self-care, treatment compliance and healthy lifestyle behaviors in individuals with HT. This research is the first randomized controlled study in which the effects of a training program that is suitable for our country's patient profile for HT self-management, shaped according to multidimensional and up-to-date guidelines, that can encourage participants to change behavior, are tested. It has the potential to provide unique contributions to the field with its potential to create infrastructure.
Trospium chloride tablets was evaluated for the treatment of patients with overactive bladder who had symptoms of urinary frequency, urgency, and urge incontinence in two U.S. 12-week, placebo-controlled studies and one 9-month open label extension.

Study 1 was a randomized, double-blind, placebo-controlled, parallel-group study in 523 patients. A total of 262 patients received trospium chloride tablets 20 mg twice daily and 261 patients received placebo. The majority of patients were Caucasian (85%) and female (74%) with a mean age of 61 years (range: 21 to 90 years). Entry criteria required that patients have urge or mixed incontinence (with a predominance of urge), urge incontinence episodes of at least 7 per week, and greater than 70 micturitions per week. The patient’s medical history and urinary diary during the treatment-free baseline confirmed the diagnosis. Reductions in urinary frequency, urge incontinence episodes and urinary void volume for placebo and trospium chloride tablets treatment groups are summarized in Table 3 and Figures 2 and 3.

Study 2 was nearly identical in design to Study 1. A total of 329 patients received trospium chloride tablets 20 mg twice daily and 329 patients received placebo. The majority of patients were Caucasian (88%) and female (82%) with a mean age of 61 years (range: 19 to 94 years). Entry criteria were identical to Study 1. Reductions in urinary frequency, urge incontinence episodes, and urinary void volume for placebo and trospium chloride tablets treatment groups are summarized in Table 4 and Figures 4 and 5.
Several temperate countries have used mass chemoprevention interventions with medicines of the 8-aminoquinoline class that prevent relapses from Plasmodium vivax before peak transmission to reduce transmission of malaria. The WHO commissioned a systematic review of the literature and evidence synthesis to inform development of recommendations regarding this intervention referred to as "mass relapse prevention" (MRP). Electronic databases were searched, 866 articles screened, and 25 assessed for eligibility after a full-text review. Two nonrandomized studies were included, one from the Democratic People's Republic of Korea (391,357 participants) and the second from the Azerbaijan Soviet Socialist Republic (∼30,000 participants). The two studies administered a single round of primaquine over 14 days (0.25 mg/kg per day). From 1 to 3 months after the treatment round, the incidence of P. vivax infections was significantly lower in areas that received MRP than those that did not (pooled rate ratio [RR] 0.08, 95% CI 0.07-0.08). At 4 to 12 months after the treatment round, the prevalence of P. vivax infection was significantly lower in MRP villages than non-MRP villages (odds ratio 0.12, 95% CI 0.03-0.52). No severe adverse events were found. The certainty of evidence for all outcomes was very low and no conclusions as to the effectiveness or safety of MRP could be drawn. However, it is not likely that this intervention will be needed in the future as most temperate countries where P. vivax is transmitted are nearing or have already eliminated malaria.
The invention relates to a health-care eyeshade which comprises a shade body covered on eyes and fixing belts and is characterized in that the shade body comprises an outer shade and dressing bags respectively installed in the outer shade corresponding to the left eye and the right eye. The outer shade is an interlayer bag formed by fixedly connecting a surface layer and an inner layer, and a left gap and a right gap which are used for replacing the dressing bags respectively are arranged at the upper edge of the outer shade. Medicine pasts are arranged on the side of the inner layer clinging to the skin corresponding to the left eye and the right eye respectively. Magnets and/or far infrared coating points are arranged on the side of the inner layer clinging to the skin corresponding to the positions around the left eye and the right eye. The dressing bags can be hot pressing bags, cold pressing bags or medicine dressing bags respectively formed by filling heating dressing, refrigerating dressing or medicine dressing in packing bags. The outer shade can be continuously used for multiple times. Different health-care modes can be achieved by replacing different dressing bags according to needs of users. In addition, the health-care eyeshade has the advantages of being simple in structure, multiple in function, convenient to operate and saving in material.
The group of participants has been genotyped to have the CYP2C19\*2 and/or CYP2C19\*3 variant during the first part of the study. The participants will consume 1 oz water mixed with 500mg limonene (Jarrow Formula orange peel extract) and be asked to swish 5 times and swallow. All participants will then provide breath samples over the course of 2 hours. The breath sample outcomes will be compared to those of the wild-type CYP2C19 study subjects.
To investigate the effects of co-infection with Clonorchis sinensis (C. sinensis) on T cell exhaustion levels in patients with chronic hepatitis B, we enrolled clinical cases in this study, including the patients with concomitant C. sinensis and HBV infection. In this study, we detected inhibitory receptors and cytokine expression in circulating CD4+ and CD8+ T cells by flow cytometry. PD-1 and TIM-3 expression levels were significantly higher on CD4+ T and CD8+ T cells from co-infected patients than on those from the HBV patients. In addition, CD4+ T cells and CD8+ T cells function were significantly inhibited by C. sinensis and HBV co-infection compared with HBV single infection, secreting lower levels of Interferon gamma (IFN-γ), Interleukin-2 (IL-2), and TNF-α. Our current results suggested that C. sinensis co-infection could exacerbate T cell exhaustion in patients with chronic hepatitis B. PD-1 and TIM-3 could be novel biomarkers for T cell exhaustion in patients with Clonorchis sinensis and chronic hepatitis B co-infection. Furthermore, it may be one possible reason for the weaker response to antiviral therapies and the chronicity of HBV infection in co-infected patients. We must realize the importance of C. sinensis treatment for HBV-infected patients. It might provide useful information for clinical doctors to choose the right treatment plans.
The present invention discloses a compound cosmetic additive containing dandelion extracts and bletilla striata extracts, a preparation technology and application of the additive in cosmetics. In the preparation technology, a standard dandelion extract is obtained by removing impurities, cleaning, cutting up and extracting dandelions by an ultrasonic immersion method, and filtering, flocculating, centrifuging, super filtering, adsorbing by macroporous resin, washing by alcohol and concentrating the dandelions. In addition, bletilla striata bulbs are selected to be cleaned, added with ethanol, pulverized, pulped, filtered, ground by a colloidal mill and placed still to centrifuge and separate; a supernatant liquid is added in edible ethanol to be stirred and is placed still in normal temperature; deposition is extracted, filtered, washed by absolute alcohol or acetone, and is added with water to be dissolved and diluted for adjusting the pH value; thus, the standard hyacinth bletilla extract is obtained. After the dandelion extract and the hyacinth bletilla extract are uniformly and proportionally mixed, the additive is prepared. The compound additive has the advantages of favorable emulsification performance, uniform dispersion, stable biologic active materials and notable functions, and is capable of being produced and applied in standardization. The compound additive can be used for developing cosmetics with the efficacy of killing bacteria, diminishing inflammation, removing speckles, whitening, resisting wrinkles, preventing senescence, etc.
The advanced MRI studies will be obtained at the time of the routinely scheduled preoperative planning MRI and/or the routinely scheduled pre-RT planning MRI at approximately 3±2 weeks after surgery. The routine sequences obtained for the planning MRI are standard of care. The advanced MRI sequences may or may not be additional as some have already been adopted into the standard of care imaging at MSKCC.
PURPOSE: To obtain a local administration composition containing miokamycin as a main ingredient, having a dosage form of ointment, suppository, pencil, etc., and used for the therapy of the microbial infectious diseases of skins and mucous membranes. CONSTITUTION: This ointment contains 1-5g of miokamycin, 0.08-0.4g of ethyl cellulose, 3-7g of a nonionic surfactant, 50-80g of a fatty acid ester mixture, 5-15g of a saturated fatty acid glyceride, and 0.05-0.2g of a preservative, wherein the total amount of the substances is 100g. The composition comprises an excipient charged in a proper bottle, and the miokamycin charged in a cap as a storage container. The contents of the bottle comprises a gel containing 0.5-3g of hydroxypropylmethylcellulose, 5-50g of poloxamer and/or poloxamine, 0.05-0.2g of a preservative, a buffering agent in an amount required for maintaining the pH at 7-7.5, and water in such an amount as giving a whole weight of 100g. The contents of the cap comprise 1-5g of miokamycin and 0.08-0.4g of ethyl cellulose. The contents of the bottle and the contents of the cap are mixed with each other, when employed.
Bacterial colonization is present in up to 95% of chronically catheterized patients. Although a positive urine culture collected from an indwelling catheter is not in isolation indicative of an acute urinary tract infection (UTI), long term catheter use is associated with increased rates of recurrent urinary tract infections (rUTI), pyelonephritis, and bacteremia. Using antibiotics for prevention of infections in this patient population can be challenging given the side effects, cost, and emergence of resistant bacteria with antibiotic therapy. To limit systemic side effects, intravesical irrigation is a promising route of medication administration. The use of a non-antibiotic anti-microbial at the time of SPC exchange would eliminate the obstacles of non-compliance and antibiotic resistance associated with antibiotic irrigation for preventive therapy. Irrisept, a 0.05% Chlorhexidine Gluconate (CHG) irrigation in sterile water, could be a promising agent to reduce symptomatic UTIs and unplanned tube changes in chronically catheterized patients.

The proposed route of intravesical instillation involves the administration of a therapeutic agent directly into the bladder via a urinary catheter. This route allows for local contact with bladder mucosa and urinary pathogens. It is a currently accepted route of administration used for therapeutics in urologic conditions including, but not limited to UTI prophylaxis, bladder cancer, hemorrhagic cystitis, and interstitial cystitis. Benefits of intravesical instillation include maximizing exposure of the therapeutic within the bladder while limiting systemic absorption and side effects.

A volume 150cc is based on current clinical administration of bladder instillations. Current intravesical drug delivery is most commonly utilized in volumes 50-150cc for in-office instillation. Population studies of normal volunteers demonstrate that 1st bladder sensation occurs between 125-200cc with subsequent desire to void occurring between 170-370cc. Increasing instillation volumes greater than 150cc, especially in the chronically catheterized population, can lead to patient discomfort or dysreflexia and inability to tolerate the therapy without analgesia or anesthetic.
Previously primed in infancy with Meningitec™ and Pediacel™ and boosted with Menitorix™ (Priorix™ co-administered). All UK subjects received a booster dose of Infanrix-IPV™ at 40 to 43 months of age, intramuscularly in the deltoid region.
Each vial of Dantrolene Sodium for Injection should be reconstituted by adding 60 mL of sterile water for injection USP (without a bacteriostatic agent), and the vial shaken until the solution is clear. 5% Dextrose Injection USP, 0.9% Sodium Chloride Injection USP, and other acidic solutions are not compatible with Dantrolene Sodium for Injection and should not be used. The contents of the vial must be protected from direct light and used within 6 hours after reconstitution. Store reconstituted solutions at controlled room temperature (59°F to 86°F or 15°C to 30°C). 

Reconstituted Dantrolene Sodium for Injection should not be transferred to large glass bottles for prophylactic infusion due to precipitate formation observed with the use of some glass bottles as reservoirs. 

For prophylactic infusion, the required number of individual vials of Dantrolene Sodium for Injection should be reconstituted as outlined above. The contents of individual vials are then transferred to a larger volume sterile intravenous plastic bag. Stability data on file indicate commercially available sterile plastic bags are acceptable drug delivery devices. However, it is recommended that the prepared infusion be inspected carefully for cloudiness and/or precipitation prior to dispensing and administration. Such solutions should not be used. While stable for 6 hours, it is recommended that the infusion be prepared immediately prior to the anticipated dosage administration time. 

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.
Per Oral Endoscopic Myotomy (POEM) is performed for various esophageal motility disorders, including achalasia and other spastic esophageal conditions. It is performed with the standard endoscope and involves dissection of the esophageal submucosa followed by cutting of the esophageal muscle. The procedure is typically completed using standard monopolar cutting knives, which are effective, but can be associated with inadvertent thermal injury and post-procedural pain due to dissemination of higher voltage. More importantly, frequent exchange of various instruments are required in order to inject within the submucosa and to coagulate bleeding vessels. The Speedboat-RSD has an integrated injection needle for submucosal injection and uses bipolar radiofrequency energy (BRF) and microwave energy to dissect tissue/coagulate vessels. In essence, injection, submucosal dissection, cutting, and coagulation can all occur with one knife (2). It is FDA approved for submucosal dissection (ESD) and myotomy within the gastrointestinal tract but only a few studies have evaluated its use in POEM (3). Currently, the investigators have been performing EGD with the POEM procedure using Speedboat-RSD as a standard of care procedure. The investigators would like to compare the performance of the standard monopolar ERBE knife to the bipolar Speedboat-RSD knife in POEM. The investigators hypothesize the bipolar knife will allow for efficient completion of the POEM procedure with less post-procedural related pain.
This is an assessor-blind randomized non-inferiority trial with an internal pilot study. Research activities will take place at the Toronto Rehabilitation Institute and the University of Toronto. For the internal pilot study, we will initially recruit 20 participants with chronic stroke and randomly assign them to one of two groups: 1) RBT, or 2) AST. Cardiorespiratory fitness, lower-extremity strength, balance control, and balance confidence will be measured pre- and post-intervention. We will calculate the final target sample size using the variability observed in this internal pilot. Additionally, a Trial Steering Committee will determine the criteria for the progression from the internal pilot to the main study, and will decide on the continuation of the internal pilot with or without modifications based on those pre-defined criteria (e.g., criteria based on feasibility or preliminary evidence of effect of the interventions from examination of effect sizes).